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Background: Urinary Bladder Cancer (UBC) is a common disease worldwide which ranks 
ninth in worldwide cancer incidence with highest incidence in developed countries. This 
study aimed at describing clinicopathological characteristics of urinary bladder cancer as 
seen at KCMC. 
Methods: This was an eight years hospital based descriptive, retrospective study conducted 
from 2006 to 2013 by using a structured data extraction form. The data were analyzed 
using SPSS software.  
Results: A total of 120 subjects were included in the study. Majority 90 (75%) had TCC 
followed by SCC (18%). Forty nine percent of subjects with TCC presented with non muscle 
invasive bladder cancer (NMIBC). Majority (87%) of subjects with non-muscle invasive TCC 
of bladder experienced recurrence within a period of one year after diagnosis. Multifocality 
and recurrence at first follow up cystoscopy are determinants of recurrence. Patients with 
NMIBC were lost to follow up giving an attrition bias of 29.5%.  
Conclusion: TCC is still the most common histological type in our set up followed by SCC. 
Majority of patients with TCC presents with advanced cancer, moreover intravesical 
recurrence after TURBT is high for those with non-muscle invasive TCC and influenced by 
multifocality and recurrence at first follow up cystoscopy. We need a large prospective 
study to confirm recurrence, progression and determinants of recurrence in our set up.  
  Introduction  
The urinary bladder is an extra peritoneal organ surrounded by pelvic fat. Its wall consist of 
four layers; urothelium, lamina propria, muscularis propria and adventitia. The urothelium 
consists of three to seven layers of transition cells. The lamina propria is very vascular layer and 
the muscularis propria consist of bundles of smooth detrusor muscle, sub divided into outer and 
inner layer. UBC is a common disease worldwide which ranks ninth in worldwide cancer 
incidence (2002) with highest incidence in developed countries; however the burden is 
expected to increase in developing countries1. 
Occurrence of UBC in developing countries is predominated by histological type that is related 
to infection and presents at advanced stage. This is expected to change as a result of economic 
growth which goes together with change and increase in prevalence of risk factors. Non muscle 
invasive bladder cancer (NMIBC) is characterized by high recurrence rate and this which made 
bladder cancer to be most expensive cancer to manage. The incidence of UBC has been rising 
over the last 60 to 70 years. The overall incidence (not age-specific incidence) of UBC in 
developing countries is lower due to several reasons one being low life expectance. 
Unfortunately, the incidence rate is rising faster in developing countries as a result of increased 
incidence of cigarette smoking, urbanization and industrialization. An estimated 386,300 new 
cases of UBC occurred in 2008 worldwide. The highest incidence rates were found in the 
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countries of Europe, North America, and Northern Africa. Epidemiological studies are 
unavailable in most African countries, however Africa was found to have low incidence of 
around 22,053 cases with Sub Saharan Africa having 45.5%(10,042)  of cases. The prevalence of 
UBC is difficult to assess due to recurrence nature of the disease. Globally at any given point in 
time, 2.7 million people have a history of UBC1-3. 
Hereditary component of bladder cancer is probably due to inheritance of low penetrance genes 
(N-acetyl transferase and glutathione-S-transferase polymorphism) which makes an individual 
susceptible to carcinogenic exposure. N-acetyl transferase (NAT-2) is enzyme needed to 
detoxify nitrosamine which is urinary bladder carcinogen. Slow acetylators have increased risk 
of UBC than fast acetylators. Glutathione- S- Transferase M1 (GSTM1) plays an important role in 
detoxification. It conjugates reactive chemicals such as arylamines and nitrosamines. Null 
GSTM1 is associated with increased risk of UBC. Also it is well documented that second degree 
relative of individual with UBC have 2 times higher risk of developing UBC compared to general 
population4. 
The percentage of UBC attributable to tobacco smoking varies between countries according to 
local habits. In Europe it accounts for 66% of cases in males and 30% in females. In UK (2010) 
cigarette smoking account for 38% and 34% of UBC cases in male and female respectively 5-6. 
In Germany cigarette smoking account for 50% of TCC while in Kenya it account for 29%. 
Squamous cell carcinoma (SCC) has also been related to cigarette smoking. Not only Active 
smoking but also passive smoking is related to UBC4, 7-8. Strong link exists between amount and 
duration of cigarette smoking. Smokeless tobacco (snuff or chewable) use is also linked to UBC, 
whereby it was found to account for 51% of UBC in female. The causative agents are thought to 
be α- and β-naphthylamine, which are secreted into the urine of smokers. In addition to tobacco 
use, there are other established bladder carcinogens including exposure to drugs like 
cyclophosphamide used in chemotherapy and consumption of high amount of phenacetin 
containing analgesics. Acroline which is a metabolite of cyclophosphamide is responsible for 
UBC as well as hemorrhagic cystitis. Therapeutic irradiation in the pelvic region as in treatment 
of testicular cancer or cervical cancer has been implicated in UBC8-9. 
Like any other cancer, diagnosis of UBC depends on pathological evaluation of resected 
specimen. Cystoscopic appearance of the tumour can be classified according to characteristic of 
tumour surface, which can either be solid or papillary. The grade and stage of the tumour can be 
predicted with reasonable accuracy by its cystoscopic appearance10. UBC is usually staged using 
Tumour Nodal and Metastasis (TNM) staging system. The system considers the depth of 
invasion of bladder (T), regional lymph node status (N), and whether the disease has spread to 
distant organs other body parts (M). TNM is a quick, acceptable and detailed system of staging 
cancer. 
Staging can be done clinically or pathologically. Pathological staging/surgical staging is based on 
histopathological finding after surgical resection of the bladder tumour and of adjacent lymph 
nodes. Clinical stage reflects pathological finding at transurethral resection of bladder tumour 
(TURBT), radiological finding and EUA. During EUA any tumour which involves other organs or 
fixed to pelvic bone is considered to be stage T4 tumours. Stage T2/T3 tumours are bimanually 
palpable and mobile after TURBT. Despite its superficial location, CIS has more aggressive 
behavior, progressing to more advanced disease, often skipping directly to dissemination. 
Bacillus Calment Guerin (BCG) is the preferred initial treatment option for CIS. Over a 10-year 
period, approximately 30% of patients remain free of tumour progression or recurrence. 
TURBT is effective in some cases. Due to recurrent and progressive behavior of the disease, 
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intravesical immunotherapy or chemotherapy has great role in reducing recurrence and 
progression. Intravesical agents provide direct access to the tumour for therapy 11-13. 
Radical cystectomy is the standard treatment for MIBC; T2-T4a, N0-NX, and M0. Other 
indications are high-risk NMIBC (T1 G3 and BCG-resistant CIS) and extensive papillary disease 
that cannot be controlled with conservative measures. Radiation as monotherapy is usually 
offered to patients who are poor surgical candidates due to advanced age or significant co-
morbid medical problems. Radiotherapy is an alternative to radical cystectomy in well-selected 
patients with MIBC however risk of local recurrence is high. Stage T2 bladder cancer has 
excellent disease control when treated with radical cystectomy. While stage T3 or greater is at 
substantial risk for failure (pelvic failure 38% at 3 years) after cystectomy only. The aim of 
treatment in metastatic disease is palliative with systemic combination chemotherapy as the 
primary treatment modality 14-15. 
Most of the work in managing UBC patients especially NMIBC, results from the frequent follow 
up cystoscopies that are considered to be necessary for the detection of recurrent disease and 
the endoscopic resection of any tumours so found. Potential for disease recurrence and 
progression even in the long term necessitates lifelong follow-up. Varieties of different follow-
up protocol have been advocated, many urologists follow a defined pattern for follow up 
cystoscopy: every three months for one year, every six months for the second, and then annually 
unless tumours recur, in which case the sequence starts again. Some advocates a follow up 
scheme according to the patient’s degree of risk16. 
In Egypt an area endemic for schistosomiasis, 70 and 60% of patients with SCC and TCC of 
bladder respectively are peasants. Most primary UBC are epithelial in origin, accounting for up 
to 95% of all UBC. TCC is a most common (90%) type of UBC in developed countries while SCC is 
common in developing countries especially in schistosoma endemic areas where it accounted 
for 72% of UBC .Egypt reported an increase in frequency of TCC and decrease in SCC within five 
years period from 20 to 66% and 73-25% respectively17-19. Tanzania also reported reversal in 
histological type whereby the frequency of SCC was found to be 65.7% and 21.5% for TCC, ten 
years later the frequency of SCC dropped to 40% while TCC increased to 50%. A recent study 
done in Tanzania showed that SCC account for 55.1% 20-21. 
Adenocarcinoma is a rare tumour which account for 0.5-2% of all UBC subcategorized as either 
urachal or non-urachal in origin as in bladder exstrophy. Often localized at the time of diagnosis, 
but muscle invasion is usually present. Non-epithelial UBC accounts for 5-10% of UBC and it 
includes rhabdomyosarcoma, teratoma, leiomyosarcoma and chondrosarcoma. Non-muscle 
invasive TCC of bladder is characterized by high recurrent rate which makes UBC to be most 
expensive cancer to manage. Studies on recurrence rate vary broadly as a result of different 
patient’s characteristics and duration of follow up. For example, in Pakistan and Greece it was 
68.4% and 35% respectively. However we could not find published study in Africa looking at 
the recurrence of UBC. One of the goals of treating NMIBC is to prevent disease progression to 
muscle invasive and metastasis. Progression varies according to characteristic of study 
population as well as duration of follow up, for instance in Korea it was found to be as high as 
11.5% while in Pakistan progression in terms of upstaging was 4.3%18,22-25. 
Multiplicity of the tumour is a prognostic factor for recurrence. In additional to multiplicity, 
grade of the tumour is also a prognostic factor with high grade lesion having high recurrence 
rate compared to low grade lesions. Other prognostic factors associated with high risk of 
recurrence include having history of previous recurrence and presence of CIS26-29. Our study 
aimed to describe clinical and pathological characteristics of urinary bladder cancer at KCMC. 
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Patients and Methods 
This was a descriptive; hospital based retrospective study that evaluated all case notes of 
patients treated for urinary bladder cancer from 2006 to 2013. All case notes of patients treated 
for urinary bladder cancer at Kilimanjaro Christian Medical Centre from Jan 2006 to Dec 2013 
were reviewed. Case notes with incomplete information which does not fulfill the requirement 
of this study were excluded from the study.  
Ethical clearance and permission was obtained from Kilimanjaro Christian Medical University 
College and Urology department at KCMC Referral Hospital. All patients’ information was kept 
confidential; no patient’s direct identifiers were used in the data collection instrument. A 
structured questionnaire was used to collect data from patient’s case notes. Data were entered 
into computer for analysis where by SPSS version 16 was used to analyze the information. 
Cross-tabulations were generated, and where comparisons were made, significance was 
considered at p-value of less than 0.05. 
Study limitations.  
This study was done at Kilimanjaro Christian Medical Centre in Moshi, thus the findings may not 
reflect a true image of urinary bladder cancer country wise. Incomplete documentation denied 
review of some case notes. 
Results 
A total of 120 case notes of patients treated for urinary bladder cancer during the study period 
of eight years were reviewed. Males were the majority at 69% (83/120) with a male to female 
ratio of 2.2:1.Their age ranged from 4 to 90 years with mean age of 58.45 years. Most 85(71%) 
of the subjects were peasants .The mean age at diagnosis of SCC was 49.3 years with male to 
female of 0.9:1 while for TCC the mean age was 62.01 years with male to female ratio of 2.9:1 
(Table 1). 
Of the 90 subjects with TCC, 44(48.9) had non-muscle invasive TCC. All subjects with stage 
Ta/T1 were managed by complete TURBT while stages T2/T3 and T4 were subjected to either 
radical cystectomy or palliative radiotherapy after TURBX. All subjects with SCC, 
Adenocarcinoma, mixed TCC/SCC and other histological types had muscle invasive cancer at 
presentation (Table 2). Of the 44(48.9%) subjects with superficial TCC, 13 (29.5%) were lost to 
follow up and hence they were excluded from the analysis. Of the remaining 31 subjects, 27 
(87.1%) experienced recurrence at least one recurrence. Among the 27(87.1%) subjects who 
suffered recurrence, 4 (13%) of them had T stage progression (Table 3).  
Twenty four patients had low grade TCC at diagnosis while the remaining seven had high grade 
TCC. All the seven patients with high grade TCC experienced recurrences (p value=0.338). 
Twenty three patients had recurrence at first check cystoscopy and all of them experienced 
recurrences in the subsequent follow ups (P values = 0.002). Sixteen subjects (52%) had 
multiple lesions at cystoscopy and all of them suffered recurrences (p value=0.043).  
Concomitant CIS was noted in 3 patients who also experienced recurrences in the course of one 
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Table 1.  Social demographic characteristics (n=120). 
 
Variable Values Number  Percentage (%) 
Age (years): Mean  58.45  - 
Range 4-90 - 
Sex: Male 83 69 
Female 37 31 
Sex ratio Male: Female 2.2:1 - 
Occupation  
  
Peasant 85 71 
Not known 7 6 
Others* 28 23 
*Others =teachers, medical doctor, pastor, market vender, student and accountant. 
Transition cell carcinoma (TCC) was the most common histological type 90 (75%) while mixed 
TCC/SCC was the least common. [Figure 1]. 
Others =Rhabdomyosarcoma& lymphoma 
Figure 1. Histological types of bladder cancer (N=120) 
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Table 2. Stages against Histological Types 
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Total  21(100) 90(100) 3(100) 1(100) 5(100) 120(100) 
Others=rhabdomyosarcoma& lymphoma 
Table 3. Cancer Progression and Recurrences (N=31). 
Progression of cancer  
No Yes Total 
27(65) (4(12.9) 31(100) 
Recurrence  
4(12.9) 27(87.1) 31(100) 
Table 4. Determinant of Recurrence (N=31). 
 
Variables  Recurrence 
No (4) Yes (27) P values 
Grade Low grade 4 20  
High grade 0 7 0.338 
Recurrence 
in 1st   check 
cystoscopy 
Yes 0 23 0.002 




Single  4 11  




No 4 24  
Yes 0 3 0.65 
Discussion  
Although our study did not aim at giving the latent period from exposure to carcinogens to 
development of UBC, this contributes to the higher prevalence of this condition in elderly people 
with mean ages of 60.2 and 61.9 years in India and Iran respectively similar to mean age of 
58.45 years in this study.30-31 This is contrary to the findings in Nigeria of a mean age of 52 
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years.  In the Nigerian study there was higher percentage of SCC compared to our study, which 
presents at an age of 10-20 years earlier than TCC.19 
The male to female ratio in different parts of world is varied. The ratios generally range 
between three and five.31 It exceeded six in some areas in Asia 30but it was less than two (1:0.9) 
in parts of East Africa.21 An analysis of our data has revealed a ratio of 2.2:1. Greater exposure to 
risk factors like cigarette smoking and industrial carcinogens may explain the male 
preponderance. The higher sex ratio in Asia is probably due to higher tendency of males to 
smoke cigarettes and females tend to present to hospital less frequently due to social reason. 
Relatively high percent of SCC was documented by previous investigator in East Africa, and it 
affects males and females almost equally due to equal exposure to schistosomiasis in 
childhood.20 
TCC is the most common variant accounting for >90% of bladder cancer in the world 
literature.30 Prevalence of SCC varies widely in different parts of the world but is higher in Africa 
especially in areas endemic for schistosomiasis like Egypt which accounts for 25% of bladder 
cancer19. In Lake Zone of Tanzania, an area endemic for schistosomiasis, the frequency of TCC 
and SCC were 40.5% and 55.1% respectively.21 
Previous investigators in Africa observed a shift of histological type toward TCC19, 20. One of the 
studies which were done at KCMC hospital fifteen years ago found frequency of TCC to be 50% 
and SCC to be 40%. The current study, we also observed the shift in histological type, 
contribution of TCC raised to 75% while that of SCC decreased to 18%. This means the shift is 
still in process and in the future the frequency of TCC and SCC might resemble those of western 
countries. Adenocarcinoma and mixed carcinoma remained rare in our study similarly to other 
studies.20, 32. Eradication of schistosomiasis has been thought to contribute to the change of 
histological type of UBC resembling those of western countries33. An effort has been made in 
Tanzania to control schistosoma infestation which is highly associated with SCC21 Furthermore 
urbanization which goes together with industrialization and smoking can as well explain 
increase in TCC. This has to be looked into in our population. 
The frequency of recurrence in our study was 87%, which is in contrary to recurrence of 68.3% 
in another study34. In the comparative study, they excluded patients with concomitant CIS and 
they looked at recurrence at three month after diagnosis. Although we had 3 patients with 
concomitant CIS, the number can be higher than that as we did not perform random bladder 
biopsies to detect CIS24. Another study documented a much lower recurrence of 32% after 
follow up for two years after diagnosis24. In that study they included young adults and some of 
the patients were given intravesical instillations which can explain the difference in recurrence 
observed. 
Progression after mean follow up of 28 months in patient with high grade superficial UBC has 
been found to be 27.1% in Pakistan26, which is higher than our progression of 13%. This 
difference can be contributed by characteristics of study population as well as duration of follow 
up. Definition of progression can also contribute because in the previous study they define 
progression as tumour involving the detrusor muscle, nodal or distant metastasis. However 
others have found progression rate of 4.3% 23, which is low compared to our finding. The lower 
progression is probably due to the fact that in the comparative study they included patients who 
were on intravesical therapy and excluded CIS cases.  
There are a lot of controversies on factors which can predict accurately intravesical recurrence 
of urinary bladder cancer. It is difficult to compare studies because different investigator use 
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different definitions for recurrence, different populations and these patients are managed 
differently. A study of patients with Ta and T1 without CIS showed that recurrence occurs in 
most patients with previous recurrences 35.  This finding was solidified by another study which 
concluded that, negative first follow up cystoscopies have a significantly lower recurrence rate 
than those with recurrence at first cystoscopy in patients with stage T1 and Ta TCC 36. We found 
the same in our study, having recurrence at first follow up cystoscopy is a predictor of 
subsequent recurrences.  
Number of tumour is the predictors of recurrence in patients with superficial TCC of bladder28, 37   
Multifocality is associated with high rate of recurrence in high grade superficial lesions 26. In our 
analysis multifocality was related to recurrence. This high recurrence rate in multiple tumours 
can be contributed by incomplete resection of tumour at diagnosis or aggressiveness of the 
disease.  
In a retrospective study of 110 patients with TCC who were not on intravesical therapy in 
Turkey, recurrence was related to grade of cancer with high grade cancer hiving high 
recurrence rate 38 .A similar finding was documented in a Chinese study39. This was different 
from our study which had 7 patients with high grade cancer and all experienced recurrence. 
However statistical test revealed no statistical significant association between grade and 
recurrence. We noted that the cooperative study conducted in Turkey was looking at both 
intravesical and extravesical recurrence. The difference can also be due to small number of 
patients with superficial TCC in our study. In our analysis three out of thirty one patients had 
concomitant CIS and all of them experienced recurrence in the first year of follow up after 
diagnosis. However statistical test did not show any significant association between recurrence 
and CIS.  
Conclusion  
TCC is still the most common histological type in our set up followed by SCC. Majority of patients 
with TCC presents with advanced cancer, moreover intravesical recurrence after TURBT is high 
for those with non-muscle invasive TCC and influenced by multifocality and recurrence at first 
follow up cystoscopy. We need a large prospective study to confirm recurrence, progression and 
determinants of recurrence in our set up.  
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